Related Content
- Big Molecule WatchJuly 16, 2025
Lupin and Zentiva Reach Agreement to Commercialize Certolizumab Pegol Biosimilar
- Life Sciences PerspectivesJuly 11, 2025
FDA’s Push for “Radical Transparency”: Key Takeaways from the Agency’s Publication of Complete Response Letters
- Big Molecule WatchJuly 10, 2025
Denosumab Updates: Wyost and Jubbonti Launch as First Denosumab Biosimilars in the U.S.
- Life Sciences PerspectivesJuly 8, 2025
A Look Ahead in Life Sciences: What We Are Tracking in the Third Quarter of 2025 and Beyond
- Life Sciences PerspectivesJuly 7, 2025
One Big Beautiful Bill Act – Tax Implications for Life Sciences Industry
- AlertJuly 7, 2025
One Big Beautiful Bill Act – Tax Implications for Life Sciences Industry
- Big Molecule WatchJuly 3, 2025
EMA Adopts Positive Opinions for Multiple Biosimilars
- AlertJuly 3, 2025
Changes to Birthright Citizenship and the Impact on Fertility and Assisted Reproduction Clinics
- Press ReleaseJuly 9, 2025
Goodwin Advises Nektar Therapeutics on Closing of $115 Million Public Offering
- Press ReleaseJuly 8, 2025
Goodwin Guides Kymera Therapeutics in $750 Million Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders with Gilead Sciences
- Awards and RankingsJuly 7, 2025
Goodwin Is Number One Law Firm for Global M&A for H1 2025
- In the PressJuly 3, 2025
Delaware Court Awards More Than $180 Million for Breach of Commercially Reasonable Efforts Obligation in Drug Development Milestone Dispute (Westlaw Today)
- Press ReleaseJuly 1, 2025
Goodwin Advised Landmark Bio in Acquisition by Artis BioSolutions to Expand Manufacturing and Commercialization of Advanced Therapies
- Press ReleaseJuly 1, 2025
SpringWorks Therapeutics Completes Acquisition by Merck KGaA, Darmstadt, Germany to Accelerate Sustainable Growth for $3.9 Billion
- Press ReleaseJune 27, 2025
Goodwin Advises ProFound Therapeutics on Strategic Collaboration with Novartis of up to $750 Million for Cardiovascular Drug Discovery
- Press ReleaseJune 26, 2025
Goodwin Advises Royalty Pharma in Transactions to Provide up to $2 Billion in Funding to Revolution Medicines